ARKG - ARK Genomic Revolution ETF
| Previous Close | 36.54 |
| Open | 36.83 |
| Bid | 36.83 x 2200 |
| Ask | 36.90 x 3200 |
| Day's Range | 36.44 - 37.12 |
| 52 Week Range | 27.62 - 37.12 |
| Volume | 171,647 |
| Avg. Volume | 176,698 |
| Net Assets | 481.37M |
| NAV | 36.81 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Daily Total Return | 9.78% |
| Beta (5Y Monthly) | 1.94 |
| Expense Ratio (net) | 0.75% |
| Inception Date | 2014-10-30 |
- ETF Trends
This Genomics ETF Has Some Coronavirus Vaccine Leverage
The race is on to find a cure for the deadly coronavirus and that competition could benefit some ETFs, including the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). ARKG includes companies that ...
- ETF Trends
Targeted ETFs to Hone in on Innovative Growth Ideas for 2020
As investors look to growth opportunities ahead, many are looking to ongoing technological breakthroughs and targeted ETF strategies to capture these growing segments and enhance a diversified portfolio. ...
- ETF Trends
Big Ideas: Technological Breakthroughs Investors Shouldn’t Miss in 2020
ARK Invest has identified five innovation platforms that are evolving today and causing an increased amount of new technological breakthroughs. Companies that are leading and benefiting from these technologies ...
- ETF Trends
Big Things Are Happening With This Genomics ETF
Investors looking for the intersection of healthcare and disruption need to look to genomics and DNA sequencing, two of the core focuses of the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG). ARKG ...
- ETF Trends
Illumina Stock Could Illuminate This Healthcare ETF
Biotech firm Illumina, Inc. (ILMN) scrapped a merger with Pacific Biosciences, but there's still a lot to like about Illumina and for investors that can't handle the stock's over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (ARKG) is an adequate proxy on the stock. ARKG allocates 10.38% of its weight to shares of Illumina, making it the ETF with the largest weight to that stock. ARKG's stablemate, the ARK Innovation ETF (ARKK) , is second with an Illumina weight of about 7%.
- ETF Trends
Get Giddy For Genomics With This ETF
With healthcare and, more specifically, biotechnology stocks and ETFs on the mend, investors may want to consider getting tactical and focusing on one of the arena’s most potent growth avenues: genomics. ...
- PR Newswire
ARK Invest Announces Primary Listing Venue Changes For ARK Genomic Revolution ETF (ARKG) And ARK Autonomous Technology & Robotics ETF (ARKQ)
ARK Investment Management LLC (ARK or ARK Invest), a New York-based investment adviser focused solely on disruptive innovation in the public equity markets, announced today plans to change the primary listing venue of the ARK Genomic Revolution ETF (ARKG) and the ARK Autonomous Technology & Robotics ETF (ARKQ) from the NYSE Arca, Inc. to the Cboe BZX Exchange, Inc. ARK anticipates that ARKG and ARKQ will begin trading on the Cboe BZX Exchange, Inc. under their current ticker symbols on December 31, 2019. No shareholder action is required as a result of this change.
- ETF Trends
Actively Managed ETFs Provide Forward-Looking Strategies
Some money managers may loathe the idea of revealing their methodology in a fully transparent actively managed ETF, but others have fully embraced the investment vehicle to provide greater value to investors. ...
- Investor's Business Daily
Genomic ETF Up 40%-Plus This Year, Approaches New Buy Point
RK Genomic Revolution ETF is up more than 40% this year, making it one of the top ETFs of 2019. But to participate in that gain, investors had to time their buys carefully.
- Zacks
Why Biotech ETFs are Surging to New Highs
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
- Zacks
A Guide to Biotech ETF Investing
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
- Zacks
Biotech Tops in November: Best ETFs & Stocks
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
- Zacks
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
- Zacks
Why Gold is Headed to Zero -- And What You Should Buy Instead
Why Gold is Headed to Zero -- And What You Should Buy Instead
- Zacks
Genomics ETFs Surge on CRISPR's Gene Editing Progress
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
- ETF Database
ARK Invest ETFs Focus on Disruptive Companies
For anyone not familiar with ARK Invest, they have a suite of ETF strategies dedicated to helping investors hone in on disruptive innovations and technologies with the potential to affect the global economy.
- ETF Trends
ARK Invest ETFs Track Disruptive Companies Changing the World
For anyone not familiar with ARK Invest, they have a suite of ETF strategies dedicated to helping investors hone in on disruptive innovations and technologies with the potential to affect the global economy. ...
- ETF Trends
An Active ETF Approach to Target Innovations in Next Generation Sequencing
There are new developments in DNA sequencing that are making a huge impact on healthcare and the direction of growth in the industry. To take advantage of this opportunity, investors can look to a targeted ETF strategy to gain exposure to this next generation of DNA sequencing. In the recent webcast, Next Generation DNA Sequencing: An Investor Field Guide, Simon Barnett, Analyst, Genomic Revolution, ARK Invest; and Tom Staudt, Chief Operating Officer, ARK Invest, sought to to size the potential investment opportunity in innovative technologies, notably those in the healthcare industry and DNA sequencing.
- Zacks
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
- ETF Trends
Next Generation DNA Sequencing: An Investor Field Guide
Next generation DNA sequencing could set the stage for a new era in medicine given its accuracy, cost-effectiveness, and soon—affordability. In the upcoming webcast, Next Generation DNA Sequencing: An ...
- Zacks
S&P 500 at Record High: 6 ETF Winners of Last Week
The S&P 500 hit record highs last week, with the index rising for the fourth consecutive week, marking its longest winning streak since March.
- Zacks
Navigating The Healthcare Industry: Science Fiction Turns to Reality
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
- Zacks
Tap Revenue Growth With These ETFs & Dump Earnings Recession
These sector ETFs could be played to highlight revenue growth in the third quarter.
- ETF Trends
How ETF Investors Could Enhance a Portfolio with Disruptive Innovative Companies
ETF investors who want to diversify into new areas of potential growth should identify areas of innovation and look to technologies that are disrupting the markets. On the recent webcast, Focusing on Disruptive ...
